Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Dopa-Responsive Dystonia Revisited
Arch Neurol 69:1558-1562, Tadic, V.,et al, 2012
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Clinicopath Conf, Dopamine-Responsive-Dystonia Caused by a Mutation in the GCH1 Gene
NEJM 355:831-839, Case 26-2006, 2006
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Spinocerebellar Ataxia Type 2 Presenting as Familial Levodopa-Responsive Parkinsonism
Ann Neurol 50:812-815, Shan,D.,et al, 2001
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Dopa Responsive Dystonia:A Treatable Condition Misdiagnosed as Cerebral Palsy
BMJ 298:1019-1020, Boyd,K.&Patterson,V., 1989
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976